Why your multiple myeloma stage is just the starting point for personalized care

Multiple myeloma exists on a spectrum, and where you fall on that spectrum changes everything about your next steps. According to the International Myeloma Working Group, multiple myeloma ranges from precursor stages, monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma, through to active, symptomatic disease. MGUS carries a low risk of progression and typically requires monitoring rather than treatment. Smoldering myeloma sits in the middle. Abnormal plasma cells are present, but symptoms haven’t yet emerged. Active Myeloma, by contrast, requires prompt treatment. The distinction between these stages directly determines whether your care team recommends watchful waiting or an immediate treatment plan.

Fear is a natural response to a diagnosis. But the lab values, imaging results, and biomarkers your care team is collecting right now are the tools that move you from uncertainty toward clarity. Modern staging is less about categorizing disease severity and more about personalizing your path forward. The next step in that process starts with decoding exactly what those numbers mean, and why certain markers matter more than others.

Decoding the lab work: M-protein, light chains, and the CRAB criteria

Before your care team can place you within any multiple myeloma staging system, they need a clear picture of what the disease is actually doing inside your body, and that picture comes from a specific set of lab tests and clinical markers.

The M-protein test is one of the most telling indicators your care team will use. Multiple myeloma is driven by abnormal plasma cells that all originate from a single, cloned cell line. Because they’re genetically identical, they produce the same abnormal antibody protein, called a monoclonal protein, or M-protein, in large quantities. M-protein is detected in the blood or urine of about 93% of patients with multiple myeloma, making it a near-universal diagnostic signal. Elevated M-protein levels indicate how active those cloned plasma cells are.

Approximately 15–20% of patients have myeloma cells that produce only light chains and no heavy chains, which means standard M-protein testing alone may not detect their disease. That’s where the Free Light Chain (FLC) assay becomes essential. Light chains are components of antibodies, either kappa or lambda, and when plasma cells are abnormal, they often shed these fragments into the bloodstream in disproportionate amounts. The FLC assay measures the ratio of kappa to lambda light chains, flagging imbalances that confirm disease activity even when M-protein results appear low or negative.

Organ damage is assessed using the CRAB criteria, the clinical standard for identifying myeloma-related complications:

• C, Calcium: Elevated blood calcium (hypercalcemia) caused by bone breakdown
• R, Renal: Kidney function decline, often reflected by high creatinine levels in blood work, a sign that M-protein deposits or calcium are straining the kidneys
• A, Anemia: Low red blood cell count from myeloma cells crowding out healthy bone marrow
• B, Bone: Lesions or fractures visible on imaging, resulting from myeloma-driven bone destruction

High creatinine, in plain terms, signals that your kidneys aren’t filtering waste efficiently, a concern that directly influences treatment choices. Understanding these markers sets the stage for what comes next. How doctors translate them into a formal stage using a refined, modern framework.

The R-ISS staging system

The R-ISS staging system for myeloma represents a meaningful step forward from earlier approaches, giving your care team a more complete, nuanced picture of where the disease stands.

The older Durie-Salmon system was developed in the 1970s and relied heavily on imaging and hemoglobin levels to estimate tumor burden. It was a reasonable framework for its era, but it didn’t account for the molecular complexity we now know drives multiple myeloma. The Revised International Staging System (R-ISS) modernizes that approach by incorporating both clinical blood markers and genetic risk factors into a single, more predictive model.

Three blood markers sit at the core of R-ISS. Albumin reflects overall nutritional status and disease stress on the body. Beta-2 Microglobulin (B2M) is shed by plasma cells, the higher its level, the greater the burden of abnormal cells circulating in your system. Lactate dehydrogenase (LDH) signals how aggressively those cells are behaving. Together, these markers paint a picture of how much the disease has taken hold, and how active it currently is.

The three R-ISS stages break down as follows: Stage I indicates lower B2M and normal LDH, suggesting a lower overall burden. Stage II sits between the two extremes. Stage III reflects elevated B2M alongside high LDH, a sign of more active disease. And here’s an important distinction. Multiple myeloma uses a different staging system than solid tumors, with stages ranging from I to III rather than including a stage IV. Myeloma staging doesn’t carry the same terminal weight, many patients at stage III respond well to treatment and achieve deep remissions.

The role of cytogenetics: understanding high-risk vs. standard-risk

Genetics are a decisive factor in multiple myeloma prognosis, one that goes far beyond what R-ISS staging alone can reveal. Once your care team has a clear picture of your M-protein levels and free light chain assay interpretation, the next layer of insight comes from analyzing the chromosomes inside your myeloma cells themselves.

FISH (Fluorescence In Situ Hybridization) testing is the standard method for detecting these chromosomal changes. It uses fluorescent probes to highlight specific genetic abnormalities within plasma cells taken directly from a bone marrow sample, giving your care team a precise map of the disease’s genetic profile.

Certain abnormalities flag a case as high-risk. The three most clinically significant markers are del(17p) deletion, a deletion on chromosome 17 that disables a key tumor-suppressing gene, along with t(4;14) translocation and t(14;16) translocation, which are chromosomal translocations that drive more aggressive disease behavior. Cytogenetic abnormalities like del(17p) deletion are key indicators of high-risk disease that require specific therapeutic approaches. Standard-risk patients, by contrast, tend to respond more predictably to conventional induction therapy.

High-risk does not mean untreatable. In the era of modern immunotherapy, including monoclonal antibodies and CAR-T cell therapies, patients with high-risk genetics are increasingly achieving deep, sustained responses. A high-risk genetic profile typically calls for a more intensive personalized care plan, often incorporating quadruplet induction regimens and longer consolidation phases.

With genetics mapped and lab values interpreted, the next piece of the diagnostic puzzle comes from imaging and biopsy, tools that confirm what’s happening at the cellular level inside your bones.

Imaging and biopsy. Confirming the cellular picture

While blood work like the M protein blood test flags abnormal protein levels that suggest myeloma is active, your care team needs a direct look at what’s happening inside the bone marrow and skeleton to confirm diagnosis and map the full extent of the disease.

A bone marrow biopsy is the definitive step for diagnosis. During the procedure, a small sample of bone marrow, typically taken from the back of the hip bone, is analyzed to determine the percentage of plasma cells present. A finding of 10% or more clonal plasma cells is a key diagnostic threshold. The procedure sounds intimidating, but it’s performed with local anesthesia and is usually completed within 30 minutes. Mild soreness for a day or two is common; serious complications are rare. The information it provides is simply irreplaceable.

Imaging has evolved significantly. Traditional skeletal surveys, a series of X-rays taken across the entire body, were the standard for decades. But imaging tests like MRI and PET-CT scans help doctors find and diagnose multiple myeloma by showing the size and location of cancer in your bones and other tissues. This matters especially when your care team is searching for plasmacytomas, discrete tumors made of abnormal plasma cells that can form in bone or soft tissue outside the marrow. PET-CT is particularly effective at locating these lesions and assessing whether the disease is active at those sites.

Together, biopsy and advanced imaging give your care team the complete cellular picture needed to build a truly personalized care plan.

What you need to know

Understanding your specific myeloma subtype and stage is the first step toward a personalized care plan, and communicating these details clearly with your care team makes all the difference in how treatment is shaped.

Multiple myeloma diagnostic criteria go well beyond a single test or number. A confirmed diagnosis requires evidence of clonal plasma cells alongside either CRAB features (elevated calcium, kidney issues, anemia, or bone lesions) or specific high-risk biomarkers identified by the International Myeloma Working Group. From there, the Revised International Staging System (R-ISS) layers in blood markers, beta-2 microglobulin, albumin, and LDH, alongside cytogenetic data to paint a fuller picture of disease risk.

Cytogenetics is particularly critical here. Identifying high-risk genetic abnormalities, such as del(17p) deletion or t(4;14) translocation, directly influences how aggressively your care team may approach treatment. And a Stage 3 classification, while significant, is best understood as a guide for treatment intensity, not a definitive prognosis. Outcomes shift considerably based on genetics, fitness, and response to therapy.

Tracking these markers over time transforms multiple myeloma from an acute crisis into a manageable chronic condition. Regular monitoring of M-protein levels, cytogenetics, and imaging results helps your care team detect changes early and adjust your personalized care plan accordingly.

Being your own advocate starts with asking the right questions. When you meet with your care team, bring these three with you:

• “What are my cytogenetics, and do I have any high-risk features?”
• “What is my R-ISS stage, and what does it mean for my treatment options?”
• “Based on my profile, am I eligible for any clinical trials?”

A multiple myeloma diagnosis is the start of a conversation, not the end of one. With the right data in hand and the right tools to interpret it, you can walk into every appointment informed, prepared, and empowered to take an active role in your care.

Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.